ClinicalBiostats

Clinical Trials

See the methods at work.

Statistical analyses of real clinical trials: design, endpoints, results and interpretation, organized by therapeutic area and linked to the methods behind them.

407 trials analyzed so far

Matching trials

384 results

SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…Phase 3Results postedn = 501NCT02034513
SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…Phase 3Results postedn = 721NCT02030600
SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.Phase 3Results postedn = 3,040NCT00002651
SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.Phase 3Results postedn = 525NCT00644228
TAILORxIndependent statistical analysis of the TAILORx phase 3 trial, focusing on 5-year disease-free survival, the Cox proportional-hazards model, hazard ratios, confidence intervals, and the trial's noninferiority design.Phase 3Results postedn = 10,273NCT00310180
TALAPRO-2Independent statistical analysis of TALAPRO-2, evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC, with detailed interpretation of radiographic progression-free survival and the trial's survival-analysis methods.Phase 3Results postedn = 1,054NCT03395197
TBTC Study 31Complete statistical analysis of TBTC Study 31, a randomized phase 3 trial of rifapentine-containing tuberculosis treatment-shortening regimens, including non-inferiority methodology, disease-free survival, safety, confidence intervals, and interpretation.Phase 3Results postedn = 2,516NCT02410772
TDF2Independent statistical analysis of the randomized TDF2 trial of tenofovir disoproxil fumarate plus emtricitabine for HIV prevention, including trial design, registered endpoints, Cox and logistic regression methods, reported results, safety, limitations, and…Phase 2/3Results postedn = 1,219NCT00448669
TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…Phase 3Results postedn = 9,779NCT00036270
TECOSComplete statistical analysis of TECOS, the randomized phase 3 study of sitagliptin versus placebo in type 2 diabetes mellitus, including non-inferiority analysis of MACE plus, Cox proportional-hazards methodology, secondary endpoints, safety, and…Phase 3Results postedn = 14,671NCT00790205
TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…Phase 3Results postedn = 2,672NCT00066703
TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…Phase 3Results postedn = 602NCT01419197
THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…Phase 3Results postedn = 11,016NCT03354429
THEMISIndependent statistical analysis of THEMIS, a randomized phase 3 trial of ticagrelor 60 mg versus placebo in patients with type 2 diabetes mellitus, including time-to-event methods, hazard ratios, confidence intervals, safety analyses,…Phase 3Results postedn = 19,271NCT01991795
THORComplete statistical analysis of the phase 3 THOR trial of erdafitinib in participants with advanced urothelial cancer and selected FGFR gene aberrations, including overall survival, trial design, statistical methodology, and interpretation.Phase 3Results postedn = 629NCT03390504
TITANIndependent statistical analysis of TITAN (NCT02489318), a randomized phase 3 trial of apalutamide plus androgen deprivation therapy versus androgen deprivation therapy in participants with metastatic hormone-sensitive prostate cancer.Phase 3Results postedn = 1,052NCT02489318
ToGAIndependent statistical analysis of the ToGA phase 3 trial of trastuzumab plus fluoropyrimidine/cisplatin versus fluoropyrimidine/cisplatin alone in patients with HER2-positive advanced gastric cancer, including survival, response, statistical methods, interpretation, and safety.Phase 3Results postedn = 584NCT01041404
TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.Phase 3Results postedn = 810NCT03875235
TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.Phase 3Results postedn = 26,449NCT00526474
TRAILBLAZER-ALZ 2A detailed statistical analysis of TRAILBLAZER-ALZ 2, a randomized phase 3 study of donanemab versus placebo in participants with early Alzheimer's disease, including endpoint results, mixed-effects models, ANCOVA, confidence intervals, and interpretation.Phase 3Results postedn = 1,736NCT04437511
TRITON3Independent statistical analysis of TRITON3, a randomized phase 3 trial of rucaparib versus physician's choice of therapy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations.Phase 3Results postedn = 405NCT02975934
TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.Phase 3Results postedn = 543NCT03901339
TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.Phase 3Results postedn = 711NCT04527991
TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.Phase 3Results postedn = 732NCT05104866
TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…Phase 3Results postedn = 437NCT03262935
VADTIndependent statistical analysis of VADT (NCT00032487), evaluating intensive versus standard glycemic control in type 2 diabetes, with a focus on major macrovascular events, hazard ratios, log-rank testing, confidence intervals, and equivalence testing.Phase 3Results postedn = 1,791NCT00032487
VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…Phase 3Results postedn = 1,140NCT02470585
VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…Phase 3Results postedn = 1,226NCT00561470
VESALIUS-CVComplete statistical analysis of VESALIUS-CV, evaluating evolocumab versus placebo in patients at high cardiovascular risk without prior myocardial infarction or stroke. Includes trial design, time-to-event endpoints, hazard ratios, confidence intervals, statistical methodology,…Phase 3Results postedn = 12,301NCT03872401
VIALE-AIndependent statistical analysis of the phase 3 VIALE-A trial of venetoclax plus azacitidine versus azacitidine in treatment-naive participants with acute myeloid leukemia who are ineligible for standard induction therapy.Phase 3Results postedn = 443NCT02993523
VICTORIAIndependent statistical analysis of the VICTORIA phase 3 trial of vericiguat versus placebo in participants with heart failure with reduced ejection fraction, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety,…Phase 3Results postedn = 5,050NCT02861534
VISIONIndependent statistical analysis of the VISION phase 3 trial of 177Lu-PSMA-617 plus best supportive/best standard of care in metastatic castrate-resistant prostate cancer, including randomized design, time-to-event endpoints, hazard ratios, response analyses, safety,…Phase 3Results postedn = 861NCT03511664
VOYAGER PADA detailed independent statistical analysis of VOYAGER PAD, the randomized phase 3 trial of rivaroxaban plus aspirin versus placebo plus aspirin in symptomatic peripheral artery disease undergoing lower-extremity peripheral revascularization.Phase 3Results postedn = 6,564NCT02504216
ZUMA-7Independent statistical analysis of ZUMA-7, the randomized phase 3 trial of axicabtagene ciloleucel versus standard of care therapy in relapsed/refractory diffuse large B-cell lymphoma, including event-free survival, response, overall survival, quality of…Phase 3Results postedn = 359NCT03391466